• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

COVID-19:放眼未来,汲取既往经验。

COVID-19: Look to the Future, Learn from the Past.

机构信息

Institute of Medical Physics, School of Physics, University of Sydney, Sydney, NSW 2006, Australia.

Center for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.

出版信息

Viruses. 2020 Oct 29;12(11):1226. doi: 10.3390/v12111226.

DOI:10.3390/v12111226
PMID:33138262
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7692564/
Abstract

There is a current pandemic of a new type of coronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The number of confirmed infected cases has been rapidly increasing. This paper analyzes the characteristics of SARS-CoV-2 in comparison with Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and influenza. COVID-19 is similar to the diseases caused by SARS-CoV and MERS-CoV virologically and etiologically, but closer to influenza in epidemiology and virulence. The comparison provides a new perspective for the future of the disease control, and offers some ideas in the prevention and control management strategy. The large number of infectious people from the origin, and the highly infectious and occult nature have been two major problems, making the virus difficult to eradicate. We thus need to contemplate the possibility of long-term co-existence with COVID-19.

摘要

目前正流行一种新型冠状病毒,即严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)。确诊感染病例数量迅速增加。本文通过与严重急性呼吸系统综合征冠状病毒(SARS-CoV)、中东呼吸系统综合征冠状病毒(MERS-CoV)和流感进行比较,分析了 SARS-CoV-2 的特征。从病毒学和病因学角度来看,COVID-19 与 SARS-CoV 和 MERS-CoV 引起的疾病相似,但在流行病学和毒力方面与流感更为接近。该比较为疾病控制的未来提供了新的视角,并为预防和控制管理策略提供了一些思路。该病毒起源时传染性极强,且具有高度传染性和隐匿性,这两个问题成为了两大难题,使病毒难以根除。因此,我们需要考虑与 COVID-19 长期共存的可能性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a43/7692564/c9269f30493d/viruses-12-01226-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a43/7692564/8c774cbd3bcd/viruses-12-01226-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a43/7692564/c9269f30493d/viruses-12-01226-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a43/7692564/8c774cbd3bcd/viruses-12-01226-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a43/7692564/c9269f30493d/viruses-12-01226-g002.jpg

相似文献

1
COVID-19: Look to the Future, Learn from the Past.COVID-19:放眼未来,汲取既往经验。
Viruses. 2020 Oct 29;12(11):1226. doi: 10.3390/v12111226.
2
Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses.SARS-CoV-2、SARS-CoV、MERS-CoV 和甲型流感病毒的比较综述。
Front Immunol. 2020 Sep 11;11:552909. doi: 10.3389/fimmu.2020.552909. eCollection 2020.
3
COVID-19, SARS and MERS: are they closely related?新型冠状病毒肺炎、严重急性呼吸综合征和中东呼吸综合征:它们有何关联?
Clin Microbiol Infect. 2020 Jun;26(6):729-734. doi: 10.1016/j.cmi.2020.03.026. Epub 2020 Mar 28.
4
Emerging coronaviruses: first SARS, second MERS and third SARS-CoV-2: epidemiological updates of COVID-19.新出现的冠状病毒:首例SARS、第二例MERS和第三例SARS-CoV-2:新型冠状病毒肺炎的流行病学新进展
Infez Med. 2020 Jun 1;28(suppl 1):6-17.
5
Can Air-Conditioning Systems Contribute to the Spread of SARS/MERS/COVID-19 Infection? Insights from a Rapid Review of the Literature.空调系统是否会导致 SARS/MERS/COVID-19 感染的传播?文献快速回顾的见解。
Int J Environ Res Public Health. 2020 Aug 20;17(17):6052. doi: 10.3390/ijerph17176052.
6
Why COVID-19 Transmission Is More Efficient and Aggressive Than Viral Transmission in Previous Coronavirus Epidemics?为何 COVID-19 的传播效率和攻击性比以往冠状病毒疫情中的病毒传播更高?
Biomolecules. 2020 Sep 11;10(9):1312. doi: 10.3390/biom10091312.
7
The unique features of SARS-CoV-2 transmission: Comparison with SARS-CoV, MERS-CoV and 2009 H1N1 pandemic influenza virus.SARS-CoV-2 传播的独特特征:与 SARS-CoV、MERS-CoV 和 2009 年 H1N1 大流行性流感病毒的比较。
Rev Med Virol. 2021 Mar;31(2):e2171. doi: 10.1002/rmv.2171. Epub 2020 Sep 18.
8
A comparative overview of COVID-19, MERS and SARS: Review article.新型冠状病毒病、中东呼吸综合征和严重急性呼吸综合征的比较概述:综述文章。
Int J Surg. 2020 Sep;81:1-8. doi: 10.1016/j.ijsu.2020.07.032. Epub 2020 Jul 26.
9
Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.新型冠状病毒肺炎、严重急性呼吸综合征和中东呼吸综合征的生物学、临床和流行病学特征,以及 ACE2 的 AutoDock 模拟
Infect Dis Poverty. 2020 Jul 20;9(1):99. doi: 10.1186/s40249-020-00691-6.
10
Epidemiology of and Risk Factors for Coronavirus Infection in Health Care Workers: A Living Rapid Review.医护人员中冠状病毒感染的流行病学和危险因素:实时快速综述。
Ann Intern Med. 2020 Jul 21;173(2):120-136. doi: 10.7326/M20-1632. Epub 2020 May 5.

引用本文的文献

1
Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future?常见炎症性皮肤病的远程皮肤病学:未来医学?
Life (Basel). 2023 Apr 18;13(4):1037. doi: 10.3390/life13041037.
2
Rapid and universal detection of SARS-CoV-2 and influenza A virus using a reusable dual-channel optic fiber immunosensor.使用可重复使用的双通道光纤免疫传感器快速且普遍地检测 SARS-CoV-2 和流感 A 病毒。
J Med Virol. 2022 Nov;94(11):5325-5335. doi: 10.1002/jmv.28015. Epub 2022 Jul 26.
3
Wonder of wonders, miracle of miracles: the unprecedented speed of COVID-19 science.

本文引用的文献

1
Infection fatality rate of COVID-19 inferred from seroprevalence data.基于血清流行率数据推断的 COVID-19 感染病死率。
Bull World Health Organ. 2021 Jan 1;99(1):19-33F. doi: 10.2471/BLT.20.265892. Epub 2020 Oct 14.
2
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.用于治疗新冠肺炎的抗病毒药物 repurposed - 世界卫生组织团结试验中期结果
N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.
3
Expression Pattern of the SARS-CoV-2 Entry Genes and in the Respiratory Tract.
神奇啊,真是神奇:新冠病毒研究速度空前。
Physiol Rev. 2022 Jul 1;102(3):1569-1577. doi: 10.1152/physrev.00010.2022. Epub 2022 Apr 21.
4
Research on Quantitative Analysis of Multiple Factors Affecting COVID-19 Spread.影响新型冠状病毒肺炎传播的多因素定量分析研究
Int J Environ Res Public Health. 2022 Mar 8;19(6):3187. doi: 10.3390/ijerph19063187.
5
Serum levels of the IgA isotype switch factor TGF-β1 are elevated in patients with COVID-19.COVID-19 患者血清 IgA 同种型转换因子 TGF-β1 水平升高。
FEBS Lett. 2021 Jul;595(13):1819-1824. doi: 10.1002/1873-3468.14104. Epub 2021 May 21.
6
Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment.SARS-CoV-2 抗体的综合概述及其在 COVID-19 预防和治疗中的可能应用。
Microb Cell Fact. 2021 Apr 22;20(1):88. doi: 10.1186/s12934-021-01576-5.
SARS-CoV-2 进入基因在呼吸道中的表达模式。
Viruses. 2020 Oct 16;12(10):1174. doi: 10.3390/v12101174.
4
A systematic review of SARS-CoV-2 vaccine candidates.SARS-CoV-2 疫苗候选物的系统评价。
Signal Transduct Target Ther. 2020 Oct 13;5(1):237. doi: 10.1038/s41392-020-00352-y.
5
Estimation of incubation period distribution of COVID-19 using disease onset forward time: A novel cross-sectional and forward follow-up study.利用发病前时间估计 COVID-19 的潜伏期分布:一项新颖的横断面和前瞻性随访研究。
Sci Adv. 2020 Aug 14;6(33):eabc1202. doi: 10.1126/sciadv.abc1202. eCollection 2020 Aug.
6
COVID-19: Time to exonerate the pangolin from the transmission of SARS-CoV-2 to humans.COVID-19:是时候为穿山甲洗脱传播 SARS-CoV-2 给人类的罪名了。
Infect Genet Evol. 2020 Oct;84:104493. doi: 10.1016/j.meegid.2020.104493. Epub 2020 Aug 5.
7
Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients.新型冠状病毒特异性 IgA 反应在 COVID-19 患者中的特征。
Eur Respir J. 2020 Aug 27;56(2). doi: 10.1183/13993003.01526-2020. Print 2020 Aug.
8
Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins.鉴定马来穿山甲体内的 SARS-CoV-2 相关冠状病毒
Nature. 2020 Jul;583(7815):282-285. doi: 10.1038/s41586-020-2169-0. Epub 2020 Mar 26.
9
Herd immunity - estimating the level required to halt the COVID-19 epidemics in affected countries.群体免疫——评估受影响国家遏制新冠疫情所需的群体免疫水平。
J Infect. 2020 Jun;80(6):e32-e33. doi: 10.1016/j.jinf.2020.03.027. Epub 2020 Mar 21.
10
Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020.估算 2020 年日本横滨钻石公主号游轮上的 2019 年冠状病毒病(COVID-19)病例的无症状比例。
Euro Surveill. 2020 Mar;25(10). doi: 10.2807/1560-7917.ES.2020.25.10.2000180.